Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States.
OBJECTIVE
To identify regional differences in recommendations for radioactive iodine remnant ablation (RRA) in early stage well-differentiated thyroid carcinoma (WDTC) within Canada and the United States.


METHODS
A cross-sectional written survey of a sample of physicians in specialties potentially involved in thyroid cancer care was performed in 2006. Participants were asked if they recommended RRA for a hypothetical 38-year-old woman with a solitary, 1.6-cm papillary carcinoma resected by total thyroidectomy. Exploratory regional comparisons were performed using Student t tests or analysis of variance. The regions studied were western Canada, eastern Canada (Ontario, the Maritimes), Quebec, the northeastern United States, the western and midwestern United States, and the southern United States. In a secondary multivariable logistic regression analysis, we explored potential relationships between individual respondent characteristics RRA recommendations.


RESULTS
Agreement with case-based RRA recommendations was measured on a Likert scale of 1 to 7 (7 = strongest agreement).


RESULTS
The effective response rate was 56.3% (486/864). There were significant differences in RRA recommendations among the regions studied (F = 11.99, 5 df, p < 0.001); national boundaries did not explain regional variations. For the sample case, the strongest support for RRA was in Quebec and the southern United States, intermediate support in eastern Canada and the northeastern United States, and the least support in western Canada and the western and midwestern United States. Academic affiliation and surgical specialty were independently inversely associated with strong RRA recommendations.


CONCLUSIONS
There are significant regional differences in physician-based RRA recommendations in early stage WDTC within Canada and the United States. Physician specialty and practice characteristics may influence RRA recommendations.
Sawka
Anna M
AM
Division of Endocrinology and Department of Medicine, University Health Network Toronto, Ontario, Canada. sawkaam@yahoo.com
Rotstein
Lorne
L
Brierley
James D
JD
Tsang
Richard W
RW
Thabane
Lehana
L
Gafni
Amiram
A
Straus
Sharon
S
Kamalanathan
Shamila
S
Zhao
Boyu
B
Goldstein
David P
DP
Rambaldini
Gloria
G
Ezzat
Shereen
S
D000328:Adult; D002170:Canada; D002291:Carcinoma, Papillary / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D005104:Expert Testimony; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D018714:Radiotherapy, Adjuvant; D013964:Thyroid Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D014481:United States
D007457:Iodine Radioisotopes